Supporting studies
Trelegy has a higher reduction in exacerbations
RWE that looked at exacerbations - tricop tripoli and Tritrial
This study clearly shows that Trelegy is superior to Trimbow
It was a balanced signal with both signals on safety and efficacy around both Trelegy and Trimbow
The pneumonia signal is small and insignificant
Bourbeau, Price and Tribute and Trivolve, Torch,
Everyone should be on a DPI
Pankovitch et al. Usmani and FRI
Everyone should use a once a day
There is no one medication for everyone. Different patient profiles may appreciate different devices
Trelegy has mortality data and trimbow does therefore it is the better medication
Vestbo et al, GOLD
Once a day clearly has benefit
Sleep data and Tripool adherence data